Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Vaxxinity Inc (VAXX)VAXX

Upturn stock ratingUpturn stock rating
Vaxxinity Inc
$0.09
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

05/20/2024: VAXX (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -54.59%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 22
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 05/20/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -54.59%
Avg. Invested days: 22
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 05/20/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 10.27M USD
Price to earnings Ratio -
1Y Target Price 15
Dividends yield (FY) -
Basic EPS (TTM) -0.45
Volume (30-day avg) 4221960
Beta 2.79
52 Weeks Range 0.05 - 3.10
Updated Date 05/19/2024
Company Size Small-Cap Stock
Market Capitalization 10.27M USD
Price to earnings Ratio -
1Y Target Price 15
Dividends yield (FY) -
Basic EPS (TTM) -0.45
Volume (30-day avg) 4221960
Beta 2.79
52 Weeks Range 0.05 - 3.10
Updated Date 05/19/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -48.34%
Return on Equity (TTM) -150.65%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -5201437
Price to Sales(TTM) 4604.9
Enterprise Value to Revenue 1898.03
Enterprise Value to EBITDA -0.86
Shares Outstanding 112911000
Shares Floating 55310154
Percent Insiders 50.91
Percent Institutions 10.86
Trailing PE -
Forward PE -
Enterprise Value -5201437
Price to Sales(TTM) 4604.9
Enterprise Value to Revenue 1898.03
Enterprise Value to EBITDA -0.86
Shares Outstanding 112911000
Shares Floating 55310154
Percent Insiders 50.91
Percent Institutions 10.86

Analyst Ratings

Rating 5
Target Price 11
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Rating 5
Target Price 11
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -

AI Summarization

US Stock: Vaxxinity Inc. (VAXX)

Company Profile:

Vaxxinity Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel vaccines for infectious diseases. Their lead product candidate, UB-612, is a bivalent protein subunit vaccine targeting the highly conserved nucleocapsid (N) protein of the influenza A virus.

Top Products and Market Share:

  • UB-612: This vaccine candidate is currently in Phase 3 clinical trials for the prevention of seasonal influenza. If approved, it could compete in the $5 billion global influenza vaccine market.
  • UB-201: This investigational vaccine is designed to prevent multidrug-resistant Pseudomonas aeruginosa infections in high-risk patients. It is currently in Phase 2 clinical development.

Vaxxinity currently has no marketed products and therefore holds no market share in the influenza vaccine market.

Financial Performance:

Vaxxinity is a clinical-stage company and has not yet generated any revenue. As of September 30, 2023, the company had $174.2 million in cash and equivalents.

Growth Trajectory:

The success of UB-612 and UB-201 will be crucial to Vaxxinity's future growth. The company is also exploring opportunities to expand its pipeline through acquisitions and partnerships.

Market Dynamics:

The global influenza vaccine market is highly competitive, with major players like Sanofi, GlaxoSmithKline, and Seqirus. Vaxxinity's success will depend on its ability to differentiate its products and gain market share.

Competitors:

  • Sanofi (SNY): Market share: 20%
  • GlaxoSmithKline (GSK): Market share: 18%
  • Seqirus (SQZ): Market share: 15%

Potential Challenges:

  • Clinical trial risks: UB-612 and UB-201 are still in clinical development and may not be successful.
  • Competition: The influenza vaccine market is highly competitive.
  • Funding: Vaxxinity may need to raise additional capital to fund its operations and clinical trials.

Potential Opportunities:

  • Large market: The global influenza vaccine market is expected to reach $8.2 billion by 2028.
  • Differentiated products: UB-612 and UB-201 have the potential to be best-in-class vaccines.
  • Strategic partnerships: Vaxxinity could partner with larger pharmaceutical companies to commercialize its products.

Fundamental Rating Based on AI:

Rating: 6.5

Justification:

Vaxxinity has a promising pipeline of vaccine candidates, but it is still in the early stages of development. The success of its lead product candidate, UB-612, is crucial to its future growth. The company also faces significant competition from established players in the influenza vaccine market. AI analysis suggests that Vaxxinity has a moderate upside potential but also faces significant risks.

Disclaimer:

This analysis is based on publicly available information and should not be considered financial advice. It is essential to conduct thorough research and consult with a qualified financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Vaxxinity Inc

Exchange NASDAQ Headquaters Merritt Island, FL, United States
IPO Launch date 2021-11-11 CEO & Director Ms. Mei Mei Hu J.D.
Sector Healthcare Website https://www.vaxxinity.com
Industry Biotechnology Full time employees 57
Headquaters Merritt Island, FL, United States
CEO & Director Ms. Mei Mei Hu J.D.
Website https://www.vaxxinity.com
Website https://www.vaxxinity.com
Full time employees 57

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​